Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2 2Phase 3 1

Status

Completed 2Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 2NIH 2INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Papillomavirus Infections 2Leukemia, Lymphocytic, Chronic, B-Cell 1Human Papillomavirus-Related Cervical Carcinoma 1Advanced Fallopian Tube Carcinoma 1

Interventions

Cisplatin 3193Cyclophosphamide 3187Carboplatin 2968Radiotherapy 2784Paclitaxel 2716Gemcitabine 2569pembrolizumab 2378Bevacizumab 2206Docetaxel 2196Fluorouracil 1848Capecitabine 1828Oxaliplatin 1738Dexamethasone 1604Nivolumab 1580Doxorubicin 1501Rituximab 1487Magnetic Resonance Spectroscopy 1382Etoposide 1345Irinotecan 1245Leucovorin 1222Drug Therapy 1202Cytarabine 1130Pemetrexed 1074fludarabine 1056Specimen Handling 1009Vincristine 964Cetuximab 943Prednisone 940Trastuzumab 940Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Diphtheria-Tetanus-acellular Pertussis Vaccines × Clear all
NCT05237947 2026-05-22

PRISMA

National Cancer Institute (NCI)

Phase 4 Active not recruiting
5,000 enrolled
Gynecologic

Human Papillomavirus-Related Cervical Carcinoma

NCT02518555 2026-04-06

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
42 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06639074 2025-10-02

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Mayo Clinic

Phase 2 Recruiting
78 enrolled
GynecologicSarcoma

Advanced Fallopian Tube Carcinoma

NCT03180034 2025-09-04

ESCUDDO

National Cancer Institute (NCI)

Phase 4 Active not recruiting
27,945 enrolled

Papillomavirus Infections

NCT01627561 2020-04-10

Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

GlaxoSmithKline

Phase 3 Completed
148 enrolled 28 charts

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡